| Literature DB >> 28505535 |
Jamerson Ferreira de Oliveira1, Talitha Santos Lima1, Débora Barbosa Vendramini-Costa2, Sybelle Christianne Batista de Lacerda Pedrosa3, Elizabeth Almeida Lafayette4, Rosali Maria Ferreira da Silva5, Sinara Monica Vitalino de Almeida6, Ricardo Olímpio de Moura7, Ana Lúcia Tasca Gois Ruiz8, João Ernesto de Carvalho9, Maria do Carmo Alves de Lima10.
Abstract
In this study, we report the synthesis and structural characterization of a series of thiosemicarbazone and 4-thiazolidinones derivatives, as well as their in vitro antiproliferative activity against eight human tumor cell lines. For the most potent compound further studies were performed evaluating cell death induction, cell cycle profile, ctDNA interaction and topoisomerase IIα inhibition. A synthetic three-step route was established for compounds (2a-e and 3a-d) with yields ranging from 32 to 95%. Regarding antiproliferative activity, compounds 2a-e and 3a-d showed mean GI50 values ranging between 1.1 μM (2b) - 84.65 μM (3d). Compound 2b was the most promising especially against colorectal adenocarcinoma (HT-29) and leukemia (K562) cells (GI50 = 0.01 μM for both cell lines). Mechanism studies demonstrated that 24 h-treatment with compound 2b (5 μM) induced phosphatidylserine residues exposition and G2/M arrest on HT-29 cells. Moreover, 2b (50 μM) was able to interact with ctDNA and inhibited topoisomerase IIα activity. These results demonstrate the importance of thiosemicarbazone, especially the derivative 2b, as a promising candidate for anticancer therapy.Entities:
Keywords: Anticancer therapy; Cellular death; DNA interaction; Medicinal chemistry; Topoisomerase inhibition
Mesh:
Substances:
Year: 2017 PMID: 28505535 DOI: 10.1016/j.ejmech.2017.05.023
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514